Vertex Pharmaceuticals (VRTX) Non Operating Income: 2012-2025
Historic Non Operating Income for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Sep 2025 value amounting to -$9.8 million.
- Vertex Pharmaceuticals' Non Operating Income rose 42.01% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.1 million, marking a year-over-year increase of 64.07%. This contributed to the annual value of -$86.1 million for FY2024, which is 277.63% down from last year.
- Vertex Pharmaceuticals' Non Operating Income amounted to -$9.8 million in Q3 2025, which was down 174.24% from $13.2 million recorded in Q2 2025.
- Vertex Pharmaceuticals' Non Operating Income's 5-year high stood at $42.4 million during Q3 2021, with a 5-year trough of -$78.1 million in Q2 2022.
- For the 3-year period, Vertex Pharmaceuticals' Non Operating Income averaged around -$11.2 million, with its median value being -$14.9 million (2024).
- Per our database at Business Quant, Vertex Pharmaceuticals' Non Operating Income crashed by 2,500.00% in 2024 and then soared by 157.14% in 2025.
- Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Non Operating Income stood at $7.1 million in 2021, then crashed by 538.03% to -$31.1 million in 2022, then spiked by 68.49% to -$9.8 million in 2023, then slumped by 52.04% to -$14.9 million in 2024, then skyrocketed by 42.01% to -$9.8 million in 2025.
- Its Non Operating Income was -$9.8 million in Q3 2025, compared to $13.2 million in Q2 2025 and -$17.6 million in Q1 2025.